Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We analysed 35 risk factors for acute
GVHD
in 291 consecutive recipients of HLA-identical sibling marrow transplants from 1975 to 1993. Of these, 16% developed moderate-to-severe acute
GVHD
following transplantation. In multivariate analysis,
GVHD
prophylaxis with monotherapy (MTX or CsA) (P = 0.015) seropositivity for several herpes viruses in the donor (P = 0.015) and seropositivity for CMV in the recipient (P = 0.037) before the transplants as well as early engraftment (P = 0.016), were the principal risk factors for
GVHD
. A high serum TNF-alpha level during conditioning therapy was also a significant risk factor in 75 recipients (P = 0.005). The risk of grades II-IV acute
GVHD
increased with the number of risk factors. Thus the cumulative incidence of acute
GVHD
was 1%, if no risk factor was present, 4% with one, 9% with two, 21% with three and 44% in patients with four risk factors. Factors reported to correlate with acute
GVHD
, such as age, diagnosis, female donor to male recipient, relative response and donor-responding capacity in MLC,
MNS blood group
antigen, splenectomy and bone marrow cell dose were not associated with acute
GVHD
in this study. Five-year survival was 24% in patients with grades II-IV
GVHD
vs 62% in patients with grades 0-I
GVHD
(P = 0.0001).
...
PMID:Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. 875 Feb 64